Treatment with gilteritinib improved survival and increased remission rates, compared with salvage chemotherapy, among patients with relapsed or refractory FLT3-mutated acute myeloid leukemia.
Treatment with SY-1425 in combination with azacitidine induced a 62% complete response rate with incomplete blood count recovery rate among unfit patients with RARA-positive AML.
Researchers report on the BRIGHT AML 1019 Phase III trial.
Researchers explore the predictive capability of EVI1 expression.
Prognostic signature associated with AML relapse risk potential harbors gene subsets that apply to only certain patient subgroups.
In this study, FLT3-IRAK1/4 inhibitor (NCGC1481) removed adaptively resistant FLT3-mutant AML cells.
The US Food and Drug Administration recently approved gilteritinib (Xospata), in addition to final trial data from the phase 3 ADMIRAL trial, making it the new standard of care for acute myeloid leukemia.
Researchers utilized a targeted next-generation sequencing (NGS) panel developed at Oregon Health & Science University to assess the clearance of mutations after therapy, clonal evolution at relapse, and combinations of mutations.
A new report suggests targeting the Gal9/TIM3-axis could help boost chances of complete remission in patients with acute myeloid leukemia.
With the exception of bladder cancer, the frequency of KDM6A gene mutations in malignancy is thought to be rather low in malignant developments.